FDA approves new option amid COVID-19-spurred sedation drug shortages
The Food and Drug Administration this week approved dexmedetomidine hydrochloride in 0.9% sodium chloride injection for the sedation of initially intubated and mechanically ventilated patients in an intensive-care setting and of non-intubated patients prior to and/or during surgical and other procedures.
The drug helps address short supplies of sedation options due to the COVID-19 public health emergency. Side effects of the drug include low blood pressure, slow heart rate and dry mouth.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…